Paul De Lay Director, Evaluation UNAIDS

Slides:



Advertisements
Similar presentations
Overview/Importance of HMIS
Advertisements

The MERG Where do we go from here? l Current context for M&E –Global level –Country level l Proposed Scope of Work l Proposed Composition l Next steps.
Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July Ties Boerma HIV Department Surveillance,
Indicators for monitoring ARV treatment outcomes.
Group III: Demand Forecasting
Delphine Sculier, MD,MPH Stop TB Department World Health Organisation Geneva, Switzerland Update on the revision of ART guidelines for TB patients.
Size and Population Density of Botswana 2009 estimate: 1.99m 61% aged % growth rate 0.85% death rate 0.5% migration 62yrs life expectancy 60%
Monitoring Systems for Antiretroviral Treatment Programs Hitesh Hurkchand.
John Aberle-Grasse CDC GAP Strategies for Building National-Scale Longitudinal Patient Monitoring Systems for HIV Treatment and Care Lusaka, October 2-5,
Monitoring and Evaluation Frameworks Kyiv, Ukraine May 23, 2006 MEASURE Evaluation.
The Implementation of the WHO Asia Pacific Treatment Metrics Dr. YU, Dongbao WHO Regional Office for the Western Pacific 20 July, 2014 Antiretroviral Treatment.
Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.
experience from Lesotho
Accelerating TB/HIV activities in Zambia Alwyn Mwinga 2007 HIV Implementers Meeting 20 June 2007.
Challenge 4: Linking TB & HIV/AIDS Programs Kayt Erdahl, Project HOPE Rodrick Nalikungwi, Project HOPE Malawi December 18, 2008.
HIV Patient ART Monitoring Meeting: International Conference Centre, Geneva March 2004 Defining the variables.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Assessing & Improving Quality of Care Newly Developed Quality of Care Tools President’s Emergency Plan for AIDS Relief Track 1.0 ART Program Meeting Seema.
Overview Burkina--- ART Population: 11 millions Prevalence: 6.6% (surveillance data) Estimate of 650,000 PLWHA 300 peoples with red cross 2000 people to.
The President’s Emergency Plan for AIDS Relief Next Generation Indicators.
Unit 8: Uses and Dissemination of HIV Sentinel Surveillance Data #3-8-1.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
Orientation on HIV care and ART Recording and Reporting System.
Global Trends in HIV/AIDS Monitoring and Evaluation Deborah Rugg, PhD Associate Director for Monitoring and Evaluation HHS/US Centers for Disease Control.
Challenges in monitoring ARV therapy A clinical and public health view of the issues involved Charlie Gilks SRM team, HIV department.
Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July
Monitoring UA 2010 in health sector 1 |1 | Monitoring progress towards Universal Access 2010 in the health sector Kevin M De Cock Ties Boerma.
Ilesh V. Jani, MD PhD Instituto Nacional de Saúde Maputo, Mozambique.
Dr. Brian Armour Trinidad and Tobago. 2004: International Best Practice Governance Structure (UNAIDS)  14 February 2001: close to 10 yrs PANCAP  62.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
WHO PMTCT ARV Guidelines 2012 Programmatic Update EFV During Pregnancy Nathan Shaffer PMTCT Technical Lead, WHO IATT Webinar 11 July, 2012.
Treatment as Prevention and Treatment 2.0 Update UN Forum on AIDS, 24 June 2011 Nicole Seguy, Zhang Lan, WHO.
HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.
Group 1 Presentation: HIV Testing in TB Patients and ART Provision.
Dr Rochelle Adams ACC Project Manager On behalf of the ACC team AWACC November 2015 Health systems Strengthening for Success and Sustainability.
Sub module 1 Introduction to HIV care and ART recording and reporting system.
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
1 |1 | Treatment 2.0 Catalyzing the Next Phase of Scale-up Decentralized, Integrated and Community-Centred Service Delivery.
Thailand Well-developed health care system 200,000 need ARV Target 50,000 on ARV 50% in Northern Thailand 50% rest of Thailand, including Bangkok.
Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
Implementing operational research for HIV treatment scale-up in resource-limited settings TB/HIV Research Priorities in Resource-Limited Settings Expert.
What systems need to be put in place to ensure Quality of Clinical systems in this phase of transition HIV Care and Rx programs and ensure sustainability.
Dr. Brian Armour Trinidad and Tobago. 2004: International Best Practice Governance Structure (UNAIDS)  14 February 2001: close to 10 yrs PANCAP  62.
Strategic Information on ART Scale up Kevin O'Reilly Department of HIV/AIDS WHO.
Improving health worldwide Implications for Monitoring of the HIV Care Cascade? Jim Todd MeSH Satellite Session IAS Durban, Monday 18 th.
Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.
Quality Improvement Program: Special Needs Plans
How differentiated care supports “Tx all” and Dr
Virginia Macdonald, Annette Verster
Monitoring and Evaluation: A Review of Terms
National and Global Monitoring of HIV Exposed, Uninfected Children
Developing a Quality Management Plan December 2005
USAID SHIFT YEAR1 Technical Strategies and Priority TA
Introducing new drugs and shorter regimen
Charles Gilks HIV Department, WHO
Tuberculosis and the President’s Emergency Plan for AIDS Relief
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
Petchsri Sirinirund Advisor to HIV/AIDS Policy and Programme
HIV Patient ART Monitoring Meeting: International Conference Centre, Geneva March 2004 Summary.
Background to ProTEST and its Role in TB/HIV Agenda-setting
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Collaborative TB/HIV activities in European Region
Planned PEPFAR TX_PVLS changes in FY19
Background & rational DEWG meeting 2009
TB Screening and Differentiated Service Delivery: State of the Art
Outlining the deliverable of 2025 Targets process
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

Paul De Lay Director, Evaluation UNAIDS UNAIDS Extended MERG Workshop Subnational and Concentrated Epidemics Geneva October 28, 2004 Paul De Lay Director, Evaluation UNAIDS

Summary and Next Steps ART patient and program monitoring ISSUES: Linking patient monitoring and program monitoring-seeking duplication!! Concerns about complexity and density of data. Need more field experience. Too much data vs not enough (drug procurement/good quality clinical care) What are costs of this? Similarities/dissimilarities with TB, and “true” chronic diseases TB invested in vertical staffing Mobile patients Concerns about staffing and training Assigning responsibilities, such as data aggregation and analysis

Summary and Next Steps ART patient and program monitoring ISSUES: Public versus private services-will this work for both? Confidentiality Especially in concentrated epidemics, ? get info on modes of transmission, etc This data set contains early warning signs for ARV resistance (adherence, stockouts, changing regimens, deaths)

Summary and Next Steps ART patient and program monitoring ISSUES: Evaluation of projects (Track One proposal) Harmonizing 3X5, PEPFAR, Track One (Indicators, reports, reporting timelines, etc) Pt clinical monitoring, health facility, subnational, national-what do we need? Standardizing demographic data, especially age cohorts (0-2, 3-4,5-14, 15 and above) ? Value of CD4 and weight gain (other laboratory and clinical) for program monitoring Need long term survival Program management requires #staff per pt, staff trained, coverage, costs

Summary and Next Steps ART patient and program monitoring ISSUES: Need start-up, current, survival, coverage, % on first line and second line Rx (How much of this can be done at subnational levels) Need to cap national level indicators Balance the need to provide guidelines and the need to learn and revise Need to draft an “operations manual” based on the draft operational framework (May need two versions-one to organize technical issues and one for country guidance. Consider including in the “Fundamentals” document)

Summary and Next Steps ART patient and program monitoring ISSUES: A lot of good work has been done to build on... Now the work needs to focus on the country level